SHREE GANESH REMEDIES
Back to All Ratios
|
SHREE GANESH REMEDIES Last 5 Year EV/Core EBITDA History
[Consolidated]
Mar2024 | Mar2020 | Mar2019 | |
---|---|---|---|
EV/Core EBITDA(x) | 19.54 | 4.09 | 4.88 |
What is the latest EV/Core EBITDA ratio of SHREE GANESH REMEDIES ?
Year | EV/Core EBITDA |
---|---|
Mar2024 | 19.54 |
Mar2020 | 4.09 |
Mar2019 | 4.88 |
How is EV/Core EBITDA of SHREE GANESH REMEDIES Trending?
Years | EV/Core EBITDA | % Change | |
---|---|---|---|
Mar2024 | 19.54 | 377.75 | |
Mar2020 | 4.09 | -16.19 | |
Mar2019 | 4.88 | - |
Other Financial Ratios of SHREE GANESH REMEDIES
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare EV/Core EBITDA ratio of peers of SHREE GANESH REMEDIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
SHREE GANESH REMEDIES | ₹968.3 Cr | 5.4% | 9% | 22% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹407,971.0 Cr | -4.6% | 0.7% | 10.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,153.0 Cr | -1.2% | 12.6% | 51.2% | Stock Analytics | |
CIPLA | ₹122,717.0 Cr | 0.7% | 6% | 9.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹109,392.0 Cr | -1.8% | -0.4% | 25.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹100,702.0 Cr | 4% | 8.9% | -1.3% | Stock Analytics |
SHREE GANESH REMEDIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SHREE GANESH REMEDIES | 5.4% |
9% |
22% |
SENSEX | 0.6% |
11% |
10.4% |
You may also like the below Video Courses